ProMIS Neurosciences Inc. Common Shares (ON) (PMN)
Stock · NASDAQ · Health Care
$8.15as of 10/16/2026
Price chart
Active signals
PMN Signal Track Record
How signals performed across all stocks →What PMN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 26 | +2.4% | 54% | September 24, 2026 |
| Bollinger Band Breakout | 18 | -10.1% | 22% | June 30, 2026 |
| 200-Day Moving Average TouchActive now | 16 | -10.7% | 19% | September 8, 2026 |
| Volume Spike | 10 | -3.6% | 40% | September 1, 2026 |
| Any 20-session window (baseline) | -5.4% | 34% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PMN
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic ol…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 10
- Website
- www.promisneurosciences.com/
Fundamentals
- 1-day range
- $8$8.87
- Market cap
- $119.54M
- P/E (trailing)
- —
- P/E (forward)
- -1.91
- EPS (trailing)
- $-12.61
- Dividend yield
- —
- Beta
- -0.36
- Avg. volume
- 78.6K
Forecasts
7 analyst ratings
ProMIS Neurosciences Inc. Common Shares (ON) Competitors
Chosen by industry and closest market cap.
- PMNProMIS Neurosciences Inc. Common Shares (ON)$8.15▼ 6.32%Market cap $119.54MP/E —$6.27$27.4
- BGMBGM Group Ltd. Class A Ordinary Shares$8.65▲ 0.70%Market cap $118.62MP/E —$6.45$303
- GNLXGenelux Corporation Common Stock$2.42▼ 2.42%Market cap $121.07MP/E —$2.29$8.54
- YARWYarrow Bioscience Inc. Common Stock$18.31▼ 8.45%Market cap $116.71MP/E —$18.16$44.28
- ANIXAnixa Biosciences Inc. Common Stock$2.67▼ 3.96%Market cap $116.70MP/E —$2.32$5.46
- TLSATiziana Life Sciences Ltd. Common Shares$1.05▲ 0.00%Market cap $123.99MP/E —$0.7615$2.2
- CPIXCumberland Pharmaceuticals Inc. Common Stock$7.18▼ 4.77%Market cap $115.07MP/E —$1.85$9.28
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PMN ProMIS Neurosciences Inc. Common Shares (ON) | $119.54M | — | $8.15 | ▼ 6.32% | $6.27$27.4 |
| BGM BGM Group Ltd. Class A Ordinary Shares | $118.62M | — | $8.65 | ▲ 0.70% | $6.45$303 |
| GNLX Genelux Corporation Common Stock | $121.07M | — | $2.42 | ▼ 2.42% | $2.29$8.54 |
| YARW Yarrow Bioscience Inc. Common Stock | $116.71M | — | $18.31 | ▼ 8.45% | $18.16$44.28 |
| ANIX Anixa Biosciences Inc. Common Stock | $116.70M | — | $2.67 | ▼ 3.96% | $2.32$5.46 |
| TLSA Tiziana Life Sciences Ltd. Common Shares | $123.99M | — | $1.05 | ▲ 0.00% | $0.7615$2.2 |
| CPIX Cumberland Pharmaceuticals Inc. Common Stock | $115.07M | — | $7.18 | ▼ 4.77% | $1.85$9.28 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Rubino Ivana · October 5, 2026 · Grant80.0K
- Johanne Kaplan · August 5, 2026 · Buy2.3K @ $13.3
- Eugene Williams · May 20, 2026 · Grant11.0K
- Eugene Williams · May 20, 2026 · Grant5.5K
- Neil K. Warma · May 20, 2026 · Grant160.0K
- Shafmaster Madge K. · May 20, 2026 · Grant11.0K
- Shafmaster Madge K. · May 20, 2026 · Grant5.5K
- Neil Cashman · May 20, 2026 · Grant50.0K
- Max A. Milbury · May 20, 2026 · Grant18.2K
- Josh Mandel-Brehm · May 20, 2026 · Grant11.0K
- Josh Mandel-Brehm · May 20, 2026 · Grant5.5K
- Johanne Kaplan · May 20, 2026 · Grant50.0K
- Alex Slanix Paul · May 20, 2026 · Grant11.0K
- Alex Slanix Paul · May 20, 2026 · Grant5.5K
- WYMAN WILLIAM W · May 20, 2026 · Grant11.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 6.14M
- Total value held
- $78.02M
- Institutional holders
- 25
- Unknown1.29M
- Unknown835.7K
- Unknown696.4K
- Unknown557.1K
- Unknown414.2K
- Unknown395.3K
- Unknown371.4K
- Unknown329.8K
- Unknown325.6K
- Unknown325.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
ProMIS Neurosciences Names Dr. Rubino as Chief Commercial Officer
ProMIS Neurosciences announced that Dr. Ivana Rubino, a veteran in Alzheimer’s and neuroscience, will serve as Chief Commercial Officer. Her experience is expected to strengthen the company’s commercial strategy and support product development. The move comes as the company seeks to advance its pipeline and expand market reach.
ProMIS Neurosciences Names Dr. Rubino as Chief Commercial Officer. ProMIS Neurosciences announced that Dr. Ivana Rubino, a veteran in Alzheimer’s and neuroscience, will serve as Chief Commercial Officer. Her experience is expected to strengthen the company’s commercial strategy and support product development. The move comes as the company seeks to advance its pipeline and expand market reach.